TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02701257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iPhone bionic pancreas
Description: An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet bionic pancreas
Description: An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet bionic pancreas
Description: An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeris Xerisol glucagon
Description: A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lilly glucagon
Description: An aqueous formulation of human glucagon with limited stability that must be changed daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lilly glucagon
Description: An aqueous formulation of human glucagon with limited stability that must be changed daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLet infusion set
Description: The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact Detach infusion set
Description: The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
Study: NCT02382744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guidance
Description: Ultrasound guidance will be used to place a saphenous nerve block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance + nerve stimulation
Description: Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
Study: NCT03743506

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: With feedback
Description: To evaluate the displacement of the center of pressure on the disc during the equilibration with feedback.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Without feedback
Description: To evaluate the displacement of the center of pressure on the disc during the equilibration without feedback.
Study: NCT00957242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
Study: NCT04243616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg, IV, Day 1 of Cycle 1-2 (3-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2, IV, Day 1,8 and 15 of Cycles 1-4 (3-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (not mandatory)
Description: Area under curve (AUC)=6, IV, Day 1 of Cycles 1-4 of Paclitaxel cycles (3-week cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 g/m\^2, IV, Day 1 of Cycles 1-4 of ddAC (2-week cycle)
Study: NCT00957242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo (1mg or 2.5mg)
Study: NCT04243616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 g/m\^2, IV, Day 1 of Cycles 1-4 of dose-dense Adriamycin (Doxorubicin) and Cyclophosphamide (ddAC) (2-week cycle)
Study: NCT05923450

Intervention type: PROCEDURE
Intervention: Colorectal Resection
Description: Radical resection of colorectal cancer
Study: NCT00192036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80 mg/m2, IV, every 21 days x 5 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
Study: NCT00868452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurasidone + (lithium or divalproex)
Description: lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + (lithium or divalproex)
Description: 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
Study: NCT01321840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific Autoregulation Therapy (SART)
Description: Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
Study: NCT01680978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 150 mcg orally daily, 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: orally daily, 6 weeks
Study: NCT04030780

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: spore-forming probiotic
Description: spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: spore-forming probiotic
Description: spore-forming probiotic administered as 1 capsule twice daily (2,5 x 109 CFU per capsule) during 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar capsules administered twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar capsules administered twice daily
Study: NCT02466568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM.CD40L Vaccine
Description: GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
Study: NCT01771458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Imatinib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor biopsy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Vemurafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Dasatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy based on molecular profiling : Abiraterone
Study: NCT02405585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L Immunotherapy
Description: HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.~Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection.
Study: NCT03554070

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber Laser Enucleation of the Prostate
Description: Thulium laser enucleation of the prostate is performed using the two-lobe or en-bloc techniques. Incision depth is limited to the circular fibers of the prostate capsule. The left lobe is enucleated first, starting at the 5 o'clock position. The endoscope is then introduced counterclockwise at the 2 o'clock position. Next, an incision is made at 12 o'clock and extended to the level of the verumontanum. The incisions at the 12 and 2 o'clock positions are connected, and the left lobe is enucleated into the bladder. The right lobe of the gland is enucleated in a similar manner: the initial incision at 7 o'clock was made clockwise, an 11 o'clock incision is then extended along the capsule to join with the previous cut. The final step is morcellation of hyperplastic nodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fiber Laser Urolase
Description: Urolase system (NTO IRE-POLUS, Russian Federation) is a thulium doped fiber laser.~Max. power of 120 W and energy of 8 J. Wavelength - 1,94 µm, incision depth - 0,2 mm.
Study: NCT01546285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure Readings on B40 Patient Monitor
Description: Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
Study: NCT01029015

Intervention type: PROCEDURE
Intervention: cystometry
Description: recording device measuring pressures though catheters placed in bladder and rectum

Intervention type: PROCEDURE
Intervention: cystometry
Description: recording device measuring pressures though catheters placed in bladder and rectum
Study: NCT05004597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: three dimensional photography using a 3dMDHead System (3dMD, Atlanta, GA, USA)
Description: A series of 3D craniofacial photos were captured using a 3dMDHead System (3dMD, Atlanta, GA, USA) within 7 days before or after the age of 1, 2, 4, 6, 9, and 12 months.
Study: NCT01044303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic Escalation
Description: Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
Study: NCT03059212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: High frequency rTMS for 3 to 10 min to increase the excitability of cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: High frequency rTMS for 3 to 10 min to increase the excitability of cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: High frequency rTMS for 3 to 10 min to increase the excitability of cortex.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training program
Description: A rehabilitation protocol that facilitates attention, memory, execution.
Study: NCT01603758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg/day or placebo will be given for 6 weeks
Study: NCT03366636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Legacy
Description: Project Legacy - Project Legacy is a 5-week, twice a week, 10 sessions small group intervention that encourages homeless and at-risk of homeless youth ages 14-19 to imagine a positive future and discuss how current risk behaviors can be a barrier to a successful adulthood. The program includes thinking about the future, the importance of positive social supports, short and long-term goal planning, and decision making. The program also includes life skills building, addressing past and current risk behaviors, linking to resources and navigating service systems, information on contraception and condoms, a healthy life plan and self-sufficiency. The 5 content core elements are the following:~* 1. Thinking about the future~* 2. Present actions to achieve future success~* 3. Safeguarding one's future~* 4. Creating a Healthy Life Plan~* 5. Navigating service systems
Study: NCT01519037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet 60 MG
Description: one dose of oral cinacalcet, 60mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: one tablet of placebo
Study: NCT00761189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
Study: NCT04554797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Hypothermia
Description: Regional hypothermia was achieved by intraarteral perfusion of cold fluid into the ischemic area of the brain
Study: NCT02947074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Meditation
Description: Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
Study: NCT00168311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TMS
Study: NCT01004042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
Study: NCT01955655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03181321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The First Twenty
Description: The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
Study: NCT03146182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRP-algorithm
Description: a strategy based on CRP guided antibiotic stewardship

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCT-algorithm
Description: a strategy based on PCT guided antibiotic stewardship
Study: NCT03196674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback via motion capture
Description: The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback via motion capture
Description: The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
Study: NCT03200691

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-DCRT or IMRT radiation
Description: Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody SHR-1210
Description: SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
Study: NCT03891017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vacuum casting
Description: Participants will be cast using vacuum casting (Ottobock Harmony) method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hydrostatic casting
Description: Participants will be cast using aqua casting method. The method of casting will be randomized via RNG. Participants will be fitted with both sockets and dynamic alignment procedures will be performed. This 15-minute fitting and alignment period will address any extreme gait deviations and initial socket discomforts. After fitting, the participant will then be given a 15-minute adjustment period to wear the device. We will then begin the assessment phase, beginning with the timed Get-Up and Go test and followed by the 6-Minute Walk test. Each patient will perform 3 rounds of each test and patient order will be determined at random. The participants will be given a 10 min break between each series of tests. At the end, a questionnaire will be given.
Study: NCT03376542

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Cardiopulmonary exercise testing on treadmill prior to coronary artery bypass grafting surgery
Study: NCT01844999

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Patient Profile - Prostate (P3P)
Description: Website supporting informed patient decision making about prostate cancer care through tailored education and coaching

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard prostate cancer information websites
Description: Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
Study: NCT01806038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RPh Counseling + Outpatient Med Dispensing at Discharge
Description: On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discharge Med Dispensing Plus Counseling - Current Practice
Description: At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
Study: NCT03001752

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap immediate implant
Description: Post-extraction implants will be inserted through open flap, without bone grafting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap immediate implant and bone grafting
Description: Post-extraction implants will be inserted through open flap, adding bone grafting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless immediate implant
Description: Post-extraction implants will be inserted without elevating flap or inserting bone grafting
Study: NCT01029015

Intervention type: PROCEDURE
Intervention: cystometry
Description: recording device measuring pressures though catheters placed in bladder and rectum

Intervention type: PROCEDURE
Intervention: polysomnography
Description: recording device measuring sleep activity through electrodes attached to the subject

Intervention type: PROCEDURE
Intervention: polysomnography
Description: recording device measuring sleep activity through electrodes attached to the subject
Study: NCT04385680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate vaginal solution 0.05%
Description: preoperative vaginal preparation
Study: NCT00847834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg
Description: Once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150mg
Description: Once a day
Study: NCT00975039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST11
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.